Carolinas HealthCare System

Research and Clinical Trials

Brief Description Principal Investigator
1.1 Primary Aims
1.1.1 To assess the event free survival (EFS) of a novel regimen incorporating brentuximab vedotin (Bv; AdcetrisTM) in the chemotherapy backbone of doxorubicin (Adriamycin), vincristine, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) in newly diagnosed high-risk cHL compared to those treated with ABVE-PC.
Kaplan, Joel Adam
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.

II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.

III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
Kaplan, Joel Adam
Primary:
To collect high quality specimens from patients with hematologic disorders and normal volunteers.
Exploratory:
Future specimen analyses will be performed to determine the differences between sick and normal cells. Data used for these comparisons will include, but are not limited to: gene expression data, DNA, RNA, epigenetics, proteomics, metabolomics, and pathway analysys.
Avalos, Belinda Rene
Primary: Compare CR in patients with relapsed/ refractory DLBCL who are candidates for AASCT treated with Denituzumab Mafodotin + RICE vs RICE.
Secondary: Evaluate Safety of denetuzumab mafodotin, Compare PFS between study arms, Compare OS between study arms, Compare proportion of patients able to adequately mobilize PBSC between study arms, Compare proportion of patients able to receive ASCT following study treatment, Compare other measure of antitumor activity between study arms
Ghosh, Nilanjan
Close